American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

VERTEX PHARMACEUTICALS INC / MA

$442.96 -0.87% NASDAQ: VRTX · 15-min delayed

BOSTON, Massachusetts
Public · NASDAQ: VRTX
6,400 employees

Visit website Follow

$113.4BMarket cap

$12.0BRevenue · FY2025

$4.0BNet income

6,400Employees

VRTXNASDAQ

1991IPO

About VERTEX PHARMACEUTICALS INC / MA

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: VRTX
Employees: 6,400
IPO date: Jul 31, 1991
Headquarters: 50 NORTHERN AVENUE
BOSTON, Massachusetts 02210
Phone: (617) 341-6393
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: VRTX Nasdaq
SEC CIK: 875320
EIN: 043039129
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow VERTEX PHARMACEUTICALS INC / MA and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $12.0B
Net income: $4.0B
Total assets: $25.6B
Market cap: $113.4B
Gross margin: 86.2%
Operating margin: 34.8%
Net margin: 32.9%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

FY2021

FY2022

FY2023

FY2024

FY2025

Revenue Net income

FY 2025

Financial statements

Income statement

Revenue: $12.0B
Cost of revenue: $1.7B
Gross profit: $10.3B
Operating expenses: $6.2B
Operating income: $4.2B
Income tax: $690.0M
Net income: $4.0B
EPS (basic): $15.46
EPS (diluted): $15.32

Balance sheet

Total assets: $25.6B
Current assets: $11.2B
Total liabilities: $7.0B
Current liabilities: $3.9B
Shareholders’ equity: $18.7B

Cash flow

Operating cash flow: $3.6B
Investing cash flow: -$945.4M
Financing cash flow: -$2.3B
Net cash flow: $515.6M

Statements via Polygon.io (SEC filings)

NASDAQ: VRTX

$442.96 -0.87%

15-minute delayed · data by Polygon.io

Past year

$366.54 $500.19

52-week range

Market cap: $113.4B
P/E ratio: 28.9
EPS (diluted): $15.32
Shares outstanding: 256.0M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jul 31, 1991

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

Profitable — net income of $4.0B in FY2025.
Revenue grew 58% from FY2021 to FY2025.
Gross margin of 86.2%, net margin 32.9%.
Trading 11% below its 52-week high.
Valued at a price-to-earnings (P/E) ratio of 28.9.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.